Browsing Tag
Amplia Therapeutics
5 posts
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
How does Amplia’s ACCENT trial compare to MPACT and POLO in pancreatic cancer response rates?
Amplia’s pancreatic cancer trial hits a 31% response rate, surpassing MPACT. Find out how it compares to POLO and what it means for future therapy options.
Can Amplia’s 31% response rate help narmafotinib break into FDA fast-track territory?
Can Amplia's narmafotinib gain FDA fast-track after 31% pancreatic cancer response rate? Explore its trial results, U.S. plans, and Project Optimus path.
Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit
Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline.
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted…